company background image
0KFH logo

Revenio Group Oyj LSE:0KFH Stock Report

Last Price

€24.44

Market Cap

€634.5m

7D

-0.7%

1Y

-29.0%

Updated

26 Apr, 2024

Data

Company Financials +

0KFH Stock Overview

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally.

0KFH fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance2/6
Financial Health5/6
Dividends3/6

Revenio Group Oyj Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Revenio Group Oyj
Historical stock prices
Current Share Price€24.44
52 Week High€38.32
52 Week Low€17.59
Beta1.31
1 Month Change-3.86%
3 Month Change-3.99%
1 Year Change-29.04%
3 Year Change-59.06%
5 Year Change21.93%
Change since IPO267.71%

Recent News & Updates

Recent updates

Shareholder Returns

0KFHGB Medical EquipmentGB Market
7D-0.7%-1.1%2.2%
1Y-29.0%-11.3%0.9%

Return vs Industry: 0KFH underperformed the UK Medical Equipment industry which returned -11.3% over the past year.

Return vs Market: 0KFH underperformed the UK Market which returned 0.9% over the past year.

Price Volatility

Is 0KFH's price volatile compared to industry and market?
0KFH volatility
0KFH Average Weekly Movement6.0%
Medical Equipment Industry Average Movement8.3%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.7%

Stable Share Price: 0KFH has not had significant price volatility in the past 3 months.

Volatility Over Time: 0KFH's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001207Jouni Toijalawww.reveniogroup.fi

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; and iCare TONOVET an IOP measuring on animal patients by general veterinary practitioners, veterinary ophthalmologists, and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; and DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.

Revenio Group Oyj Fundamentals Summary

How do Revenio Group Oyj's earnings and revenue compare to its market cap?
0KFH fundamental statistics
Market cap€634.50m
Earnings (TTM)€19.11m
Revenue (TTM)€96.79m

33.2x

P/E Ratio

6.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0KFH income statement (TTM)
Revenue€96.79m
Cost of Revenue€28.34m
Gross Profit€68.44m
Other Expenses€49.34m
Earnings€19.11m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 08, 2024

Earnings per share (EPS)0.72
Gross Margin70.72%
Net Profit Margin19.74%
Debt/Equity Ratio14.3%

How did 0KFH perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

53%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.